Multicenter international phase II study of oral vinorelbine (NVBo), capecitabine (X) and trastuzumab (H) triple combination in HER2-positive metastatic breast cancer (MBC): updated results with a longer follow-up.

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Triple Combination ◽

Her2 Positive ◽

Phase II study of the combination of oral vinorelbine (NVBo), capecitabine (X), and trastuzumab (H) in HER2-positive, metastatic breast cancer (MBC): Recent analysis of the results with a median follow-up of 44 months.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.1077 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 1077-1077 ◽

Cited By ~ 4

Author(s):

L. B. Petruzelka ◽

V. Ganju ◽

D. Becquart ◽

P. F. Conte ◽

N. Tubiana-Mathieu ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Recent Analysis ◽

Her2 Positive ◽

232 Final Results of a Phase II Study of the Combination of Oral Vinorelbine (NVBo), Capecitabine (X) and Trastuzumab (H) in HER2-positive Metastatic Breast Cancer (MBC)

European Journal of Cancer ◽

10.1016/s0959-8049(12)70300-3 ◽

2012 ◽

Vol 48 ◽

pp. S110

Author(s):

L. Petruzelka ◽

V. Ganju ◽

P.F. Conte ◽

N. Tubiana-Mathieu ◽

F. Majois ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Her2 Positive ◽

First-line trastuzumab (H), oral vinorelbine (NVBo) and capecitabine (X) combination therapy for HER2-positive metastatic breast cancer (MBC): efficacy and safety in a multinational phase II study

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(08)70894-2 ◽

2008 ◽

Vol 6 (7) ◽

pp. 220-221

Author(s):

A. Chan ◽

V. Ganju ◽

D. Becquart ◽

P.F. Conte ◽

L. Petruzelka ◽

...

Keyword(s):

Breast Cancer ◽

Combination Therapy ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Efficacy And Safety ◽

First Line ◽

Her2 Positive ◽

5055 High efficacy of the combination of oral vinorelbine (NVBo), capecitabine (X) and trastuzumab (H) in HER2-positive metastatic breast cancer (MBC): updated results of an international phase II trial with a median follow-up of 39 months

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)70947-4 ◽

2009 ◽

Vol 7 (2) ◽

pp. 277 ◽

Cited By ~ 2

Author(s):

A. Chan ◽

V. Ganju ◽

D. Becquart ◽

P.F. Conte ◽

L. Petruzelka ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

High Efficacy ◽

Her2 Positive ◽

Safety of Herceptin monotherapy administered on a 3-weekly schedule: Preliminary data from a phase II study in women with HER2-positive metastatic breast cancer

European Journal of Cancer ◽

10.1016/s0959-8049(02)80299-4 ◽

2002 ◽

Vol 38 (11) ◽

pp. S95

Author(s):

J Baselga

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Preliminary Data ◽

Phase Ii Study ◽

Metastatic Breast ◽

Weekly Schedule ◽

Her2 Positive

SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (with or without letrozole in ER+) in previously trastuzumab-pretreated, postmenopausal patients with HER2-positive metastatic breast cancer

Annals of Oncology ◽

10.1093/annonc/mdx365.084 ◽

2017 ◽

Vol 28 ◽

pp. v106-v107 ◽

Cited By ~ 3

Author(s):

P. Villagrasa Gonzalez ◽

A. Prat ◽

M. Oliveira ◽

L. de la Pena ◽

X. Gonzalez ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Her2 Positive

Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study

Breast Cancer Research and Treatment ◽

10.1007/s10549-017-4203-y ◽

2017 ◽

Vol 163 (3) ◽

pp. 507-515 ◽

Cited By ~ 3

Author(s):

Konstantinos Tryfonidis ◽

◽

S. Marreaud ◽

H. Khaled ◽

B. De Valk ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Extracellular Domain ◽

Cardiac Safety ◽

Her2 Positive ◽

Serial Serum

Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy

Annals of Oncology ◽

10.1093/annonc/mdx365.015 ◽

2017 ◽

Vol 28 ◽

pp. v81

Author(s):

N.M. Iyengar ◽

L.M. Smyth ◽

D. Lake ◽

A. Gucalp ◽

J.C. Singh ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Her2 Positive

All-oral combination of oral vinorelbine (NVBo) and capecitabine (X) in HER2-negative metastatic breast cancer (MBC): latest results of a multicenter, international phase II trial with a median follow-up of 37.7 months.

10.1158/0008-5472.sabcs-6125 ◽

2009 ◽

Author(s):

N Tubiana-Mathieu ◽

P Bougnoux ◽

D Becquart ◽

A Chan ◽

F Majois ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Abstract OT1-1-13: A phase II study with lead-in safety cohort of cabazitaxel plus lapatinib as therapy for patients with HER2-positive metastatic breast cancer (MBC) and intracranial metastases

10.1158/0008-5472.sabcs13-ot1-1-13 ◽

2013 ◽

Author(s):

DA Yardley ◽

JD Hainsworth ◽

E Hamilton ◽

LL Hart ◽

M Shastry ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Her2 Positive ◽

Intracranial Metastases